Trulieve Stock Surges Amid Cannabis Rescheduling Hopes

Trulieve Cannabis Corp (TCNNF) has experienced a significant surge in its stock price, driven by renewed hopes for cannabis rescheduling. On December 12, 2023, the stock rallied by an impressive 66%, and it has risen 91% since the beginning of the year. This upward movement comes after the stock hit an all-time low of $3.02 in April 2023.

Despite the recent optimism surrounding Trulieve, analysts caution about potential pitfalls. The company’s valuation may appear attractive at 4.8x projected EBITDA for 2025, but several factors could pose significant risks. These include substantial tax liabilities and aggressive margin assumptions that could lead to material downside risks for investors.

Florida, where Trulieve operates approximately 70% of its stores, remains crucial to the company’s performance. However, analysts have noted flat unit sales and declining dollar volumes in the state, suggesting possible market saturation and increased pressure on profit margins.

Tax Implications and Future Outlook

The potential rescheduling of cannabis at the federal level would eliminate the burdensome 280E taxation, which taxes cannabis businesses at a much higher rate due to their illegal status under federal law. This change could improve Trulieve’s cash flow significantly. Nevertheless, rescheduling does not guarantee any regulatory or listing changes, meaning the outlook for 2026 EBITDA remains negative.

Investors are advised to consider reallocating into other cannabis stocks or stepping back from the market. The current excitement surrounding Trulieve may not be enough to offset the mounting challenges facing the company.

As the cannabis industry continues to evolve, staying informed about financial health and market trends will be essential for investors. The recent rally may provide a momentary boost, but sustainable growth will depend on broader regulatory changes and market dynamics.

According to Seeking Alpha, analysts urge caution, emphasizing that past performance is not indicative of future results. Investors should conduct thorough research before making decisions regarding their investments in cannabis stocks.

In summary, while Trulieve’s stock rally is noteworthy, potential investors should weigh the risks alongside the opportunities, especially in light of the current market conditions.